Interview of EORTC members about COVID-19 impact on cancer clinical trials
4 Feb 2021
The COVID-19 pandemic has affected cancer clinical trials in many ways, creating challenges and new opportunities.
Recruitment of many studies slowed down, patients did not dare to go to the hospital due to the fear of infection and mobility limitations as shortage of research staff.
During the pandemic, clinical investigators had to adapt quickly to continue the follow-up of their patients by setting remote monitoring, remote dispensation of medications for patients, telematics clinical visits, etc.
Our members share their stories on the impact of the pandemic and how they overcame the challenges, which resulted in being beneficial to patients.
Watch the interviews of our members:
Prof. Josep Tabernero, Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain
Prof. Yolande Lievens, UZ Ghent, Belgium
Prof. Piotr Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Prof. Kristin Bjordal, University of Oslo, Norway
Prof. Jean-Yves Blay, Centre Léon Bérard, Lyon, France
Related News
New European AI assistant to make patient experiences actionable for care and health systems
12 Nov 2026
First site activated in EORTC STARBURST-1, the research project on muscle-invasive bladder cancer
28 Oct 2026
EORTC at ESMO 2026: New findings and ongoing studies
27 Oct 2026
EORTC research presented at ESMO 2026
22 Oct 2026
EORTC Quality of Life Group at ISOQOL 2026
15 Oct 2026
Pink October 2026: Advancing breast cancer research, together
7 Oct 2026
EORTC presents new results in neuro-oncology at EANO
28 Sep 2026
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
